2013年以來(lái)國(guó)家藥品監(jiān)管部門(mén)批準(zhǔn)了91個(gè)品種的78個(gè)補(bǔ)充檢驗(yàn)方法和檢驗(yàn)項(xiàng)目，2014-2019年國(guó)家藥品抽檢中通過(guò)補(bǔ)充檢驗(yàn)方法和檢驗(yàn)項(xiàng)目檢出13個(gè)品種83批次的摻雜摻假藥品，占檢驗(yàn)批次4.7%，對(duì)打擊摻雜摻假藥品和行為，保護(hù)公眾用藥安全發(fā)揮了重要作用。今后的工作中，建議相關(guān)單位正確理解單獨(dú)出具補(bǔ)充檢驗(yàn)報(bào)告書(shū)的要求和補(bǔ)充檢驗(yàn)方法和檢驗(yàn)項(xiàng)目的溯及既往的屬性，并且充分利用探索性研究和跟蹤抽檢等手段擴(kuò)大抽檢成果，加大處罰力度，嚴(yán)厲打擊藥品摻雜摻假。

The national drug regulatory authority has approved 78 supplementary testing methods and items for 91 drugs since 2013. In the national drug sampling and testing during 2014 to 2019, 83 batches counterfeit drugs of 13 varieties were detected through the approved supplementary testing methods and items, with the detection rate of 4.7%, which played an important role in counterfeit drugs and protecting public safety. In the future work, it is suggested that relevant units correctly understand the requirements for the supplementary testing report and the traceability of supplementary testing methods and items, make full use of exploratory research and follow-up sampling and testing to expand the results,and reinforce the punishment to crack down on counterfeit drugs.

R927.1